OC
BCRX icon

Oppenheimer & Co’s BioCryst Pharmaceuticals BCRX Stock Holding History

Oppenheimer & Co’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-10,000
Closed -$158K – 1491
2021
Q2 		$158K Buy
+10,000
New +$136K ﹤0.01% 1445

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Oppenheimer & Co's BCRX Position: Q3 2021 in Review

Oppenheimer & Co sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2021, closing a stake of 10,000 shares — an estimated $158K sold.

Oppenheimer & Co first reported a position in BCRX in Q2 2021 and held it in 1 quarter. The position peaked at $158K in Q2 2021. 197 funds tracked by Wall St. Rank hold BCRX as of Q3 2021.

  • Oppenheimer & Co reported no remaining BioCryst Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Oppenheimer & Co sold 10,000 BioCryst Pharmaceuticals shares in Q3 2021, an estimated $158K.
  • Oppenheimer & Co first reported a position in BioCryst Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Oppenheimer & Co's BioCryst Pharmaceuticals position peaked at $158K in Q2 2021.
  • 197 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2021.

Based on Oppenheimer & Co's 13F filing for Q3 2021, filed 12 Nov 2021.